Flatiron Health Highlights New UK Partnership

Flatiron Health Highlights New UK Partnership

Highlights

  • Flatiron Health and LTHT Unite in a progressive collaboration for Cancer Research Advancements

  • The partnership brings worldwide doctors, software engineers, epidemiologists, and data scientist to utilize the patients’ cancer data to research and provide better cancer treatments to UK patients

Flatiron Health and LTHT (Leeds Teaching Hospitals NHS Trust) have joined forces to enhance cancer research and elevate patient care in the UK. Flatiron Health aims to leverage cancer patients’ experiences to generate valuable research data for global use, fostering advancements in healthcare.

 

Each year, about 375,000 people in the UK are diagnosed with cancer, emphasizing the critical need for optimal medical care. Unfortunately, only 20% of cancer patients can participate in clinical trials, hindering comprehensive research efforts.

 

The collaboration, approved by the NHS Health Research Authority for ethical healthcare standards, aims to enhance the precision and utility of cancer data, promoting meaningful progress in research and patient care.

 

Flatiron CEO Carolyn Starrett said, “Flatiron Health worked together with partners, regulators, and patient advocates to create specific program in the UK. They have created an approach to transform data gathered during regular healthcare visits into datasets that can be utilised for research through efficient and secure techniques.”

Flatiron CEO Carolyn Starrett added, “We are delighted to work with a foremost healthcare organization in the UK. To further impact treatment decisions, medical developments, and regulatory decision-making, our cooperation intends to include more actual patient experiences.”

In partnership with LTHT, Flatiron UK has fortified the security of cancer information, planning to anonymize the data for researchers to apply in refining cancer care and treatment. This collaboration reflects Flatiron’s strategic expansion efforts into countries like Japan, Germany, and the UK, establishing partnerships with institutions such as Japan’s National Cancer Centre Hospital East.

The company envisions creating robust collections of cancer information by collaborating with hospitals, health networks, and pharmaceutical companies, expediting progress in cancer research.

Flatiron Head of Corporate Development Senior Vice-President Nathan Hubbard said, “With the help of this influential contract with Leeds Teaching Hospitals NHS Trust, which was approved by the NHS Health Research Authority, we are now able to show how we can fulfil our goal of the use of Flatiron’s expertise in real-world data to collaborate with hospitals and health networks in Europe and other parts of the world.”

Related post

Illumina Releases Next-Generation Benchtop Sequencers

Illumina Releases Next-Generation Benchtop Sequencers

Highlights Illumina has introduced the MiSeq i100 Series, a benchtop next-generation sequencing system The sequencing system is available in two configurations:…
What Does Medtronic’s CE Mark Approval for the Endoflip System Mean for Patients?

What Does Medtronic’s CE Mark Approval for the Endoflip…

Highlights Medtronic has received CE Mark approval for its next-generation Endoflip 300 system for oesophageal diagnostics The Endoflip 300 System helps…
How Will the UK’s New Draft Medical Devices Regulations Impact the Healthcare Industry?

How Will the UK’s New Draft Medical Devices Regulations…

Highlights MHRA has launched a consultation on new regulations for medical devices and in vitro diagnostics Baroness Gillian Merron emphasises these…